REDUCE-IT Trial and Triglyceride-Lowering Agents

Author(s):

Pam Taub, MD, FACC, FASPC,Michael Koren, MD, FACC

The panel of medical experts addresses the challenges in raising awareness among healthcare providers about various medications and the need for increased awareness of the REDUCE-IT trial outcomes.

EP: 1.Overview of Low-Density Lipoprotein Cholesterol Management

EP: 2.Stricter LDL-C Targets: Explaining Goalpost Changes to Patients

EP: 3.Ongoing Lp(a) Trials and Clinical Approaches to Treatment

EP: 4.Innovations in Small Interfering RNA (siRNA) Therapy

EP: 5.Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data

EP: 6.Evaluating Safety of Novel LDL Management Mechanism

EP: 7.Examining Results from VICTORION-INITIATE Trial

EP: 8.Other Notable Emerging Lipid-Lowering Treatments

Now Viewing

REDUCE-IT Trial and Triglyceride-Lowering Agents

EP: 1.Overview of Low-Density Lipoprotein Cholesterol Management

EP: 2.Stricter LDL-C Targets: Explaining Goalpost Changes to Patients

EP: 3.Ongoing Lp(a) Trials and Clinical Approaches to Treatment

EP: 4.Innovations in Small Interfering RNA (siRNA) Therapy

EP: 5.Optimizing PCSK9 Inhibitors and Analyzing Plaque Reduction Data

EP: 6.Evaluating Safety of Novel LDL Management Mechanism

EP: 7.Examining Results from VICTORION-INITIATE Trial

EP: 8.Other Notable Emerging Lipid-Lowering Treatments

EP: 9.REDUCE-IT Trial and Triglyceride-Lowering Agents

EP: 10.Diabetes, GLP-1, and Lipid Reduction

EP: 11.Medication Adherence in Patients with High LDL Cholesterol

EP: 12.Overcoming Prior Authorization Barriers in LDL Cholesterol Therapies

EP: 13.Cardiometabolic Medicine: Seeing the Patient as a Whole